A new clinical trial involving glatiramer was listed on ClinicalTrials.gov as of October 1, 2026. The study, titled "Immunotherapy With Glatiramer Acetate in PLWHIV in Poor Immunological Responders on Antiretroviral Therapy," is registered under identifier NCT07851337. It is designated a Phase 2 trial.
According to the registration, the trial's current status is not yet recruiting. The study focuses on people living with HIV who are classified as poor immunological responders while on antiretroviral therapy. No enrollment has begun and no outcomes or interim data have been reported at this stage.
This update reflects only the trial's registration status and design as entered in the public record. No efficacy, safety, or results information is available at this time, and none should be inferred from the registration itself. Further details, including recruitment timelines and study design specifics, may be updated as the trial progresses through ClinicalTrials.gov.
Readers interested in background on this compound, including its approved uses and regulatory status, can consult the compound overview for additional context.